| Not Yet Recruiting | Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Ma NCT07335328 | Medical College of Wisconsin | Phase 1 |
| Withdrawn | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin L NCT07049432 | University of Utah | Phase 1 |
| Active Not Recruiting | Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma NCT07480837 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab NCT07097363 | University of Washington | Phase 2 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Not Yet Recruiting | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL a NCT05779930 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relaps NCT07123454 | AstraZeneca | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT07068906 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Ly NCT07053670 | Tongji Hospital | Phase 1 |
| Not Yet Recruiting | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Ly NCT07032324 | Qian Wenbin | Phase 1 |
| Not Yet Recruiting | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma NCT07024147 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non- NCT07072169 | Ruijin Hospital | Phase 1 |
| Recruiting | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell NCT06879340 | University of Kansas Medical Center | Phase 1 |
| Recruiting | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Ly NCT06822868 | Kai Hu | Phase 1 |
| Recruiting | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Ly NCT06734871 | Aibin Liang，MD，Ph.D. | Phase 1 |
| Not Yet Recruiting | ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for H NCT06646666 | Ruijin Hospital | Phase 2 |
| Recruiting | Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NH NCT06707259 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL NCT06526793 | AstraZeneca | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients W NCT06242834 | Northwestern University | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell NCT06392477 | Sanofi | Phase 1 |
| Recruiting | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Ch NCT06497452 | The First Affiliated Hospital of Soochow University | — |
| Recruiting | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775 | Miltenyi Biomedicine GmbH | N/A |
| Recruiting | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphom NCT05991388 | University of Birmingham | Phase 2 / Phase 3 |
| Active Not Recruiting | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in NCT06464185 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognost NCT06365671 | Ruijin Hospital | Phase 2 |
| Recruiting | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin L NCT06251180 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Unknown | Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study NCT05927558 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, NCT05702853 | Medical University of South Carolina | Phase 1 / Phase 2 |
| Recruiting | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas NCT05365659 | Iksuda Therapeutics Ltd. | Phase 1 |
| Completed | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia NCT06027957 | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 |
| Recruiting | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem C NCT05432635 | City of Hope Medical Center | Phase 1 |
| Recruiting | Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 6 NCT06052826 | City of Hope Medical Center | Phase 2 |
| Unknown | Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells NCT05744037 | The Affiliated Hospital of Xuzhou Medical University | Phase 2 |
| Unknown | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgki NCT05667155 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cel NCT05472558 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Terminated | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies NCT05094206 | Medical College of Wisconsin | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other An NCT04970901 | ADC Therapeutics S.A. | Phase 1 |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Recruiting | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymph NCT05338931 | AbClon | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monother NCT05201248 | Genmab | Phase 1 / Phase 2 |
| Completed | Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin NCT04359784 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma NCT06725524 | Shanghai JMT-Bio Inc. | Phase 1 |
| Completed | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma NCT04836195 | Pacylex Pharmaceuticals | Phase 1 |
| Unknown | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cel NCT04887012 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Recruiting | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma NCT04594642 | AstraZeneca | Phase 1 |
| Unknown | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin NCT05164770 | Shandong Provincial Hospital | Phase 3 |
| Completed | Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With He NCT04748185 | Mayo Clinic | — |
| Active Not Recruiting | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma NCT04257578 | University of Washington | Phase 1 / Phase 2 |
| Unknown | Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma NCT04296461 | UWELL Biopharma | Phase 1 |
| Unknown | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL NCT04412174 | Hebei Yanda Ludaopei Hospital | EARLY_Phase 1 |
| Completed | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195 | Precision BioSciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy NCT04148430 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies NCT04088890 | Matthew Frank | Phase 1 |
| Unknown | Treatment of Hematological Malignancy With Novel CAR-T Cells. NCT04191941 | Timmune Biotech Inc. | EARLY_Phase 1 |
| Terminated | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma NCT03778073 | TG Therapeutics, Inc. | Phase 1 |
| Completed | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (B NCT03677141 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) NCT03870945 | Miltenyi Biomedicine GmbH | Phase 1 |
| Suspended | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma NCT03704714 | Northwestern University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedot NCT03671018 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Active Not Recruiting | Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Rec NCT03505762 | Wake Forest University Health Sciences | Phase 2 |
| Completed | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade NCT03410901 | Ronald Levy | Phase 1 |
| Completed | A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects NCT03483688 | Peking Union Medical College Hospital | Phase 1 |
| Active Not Recruiting | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL NCT03283137 | University of Chicago | Phase 1 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Active Not Recruiting | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance NCT03114865 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Terminated | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation NCT02981914 | University of Chicago | EARLY_Phase 1 |
| Completed | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B- NCT02910063 | Amgen | Phase 2 / Phase 3 |
| Completed | Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric On NCT02847130 | Children's Oncology Group | — |
| Terminated | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent NCT02928510 | Jonsson Comprehensive Cancer Center | — |
| Active Not Recruiting | DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell N NCT02633111 | Memorial Sloan Kettering Cancer Center | — |
| Completed | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Tr NCT02424968 | Robert Lowsky | Phase 2 |
| Terminated | Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cel NCT02151903 | Alopexx Oncology, LLC | Phase 1 / Phase 2 |
| Terminated | A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL NCT01874288 | Alopexx Oncology, LLC | Phase 1 / Phase 2 |
| Completed | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malig NCT01919619 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: NCT01516580 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients Wi NCT00992446 | Fred Hutchinson Cancer Center | Phase 2 |